Treatment of myasthenia gravis in france: A retrospective claims database study (STAMINA)
This study illustrates the complexity of MG management. Significant CS sparing was observed over time. The frequent treatment changes especially in patients with an immunomodulator treatment reflect the high variability of the disease severity. The need for personalised treatment approaches in the management of MG to reduce the burden of disease remains.
Authors
- Stephane Bouée (ORCID: https://orcid.org/0000-0001-6838-2680)
- Camille Nevoret (ORCID: https://orcid.org/0000-0002-5485-1535)
- Pascal Laforêt (ORCID: https://orcid.org/0000-0002-4489-4718)
- Anne Crochard
- Emmanuelle Salort‐Campana (ORCID: https://orcid.org/0000-0002-1846-3017)
- Céline Tard (ORCID: https://orcid.org/0000-0002-6654-8090)
- Gérard Chollet (ORCID: https://orcid.org/0000-0003-4245-146X)
- Gérard de Pouvourville (ORCID: https://orcid.org/0000-0002-5941-6823)
Institutions
- École Supérieure des Sciences Économiques et Commerciales (FR)
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris-Saclay (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Cemka-Eval (France) (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- UCB Pharma (France) (FR)
- Hôpital Raymond-Poincaré (FR)
- Université Lille Nord de France (FR)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1007/s00415-024-12714-5
- Citations
- 6
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 2.21
Funders
- UCB Pharma